These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 14653214)

  • 21. [Non alcoholic steatohepatitis: an emergent and potentially serious pathology].
    Elloumi H; Arfaoui D; Joudène M; Sriha B; Korbi M; Ajmi S
    Tunis Med; 2004 Jun; 82(6):484-91. PubMed ID: 15517946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonalcoholic steatohepatitis.
    Brunt EM
    Semin Liver Dis; 2004 Feb; 24(1):3-20. PubMed ID: 15085483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis.
    Shimada M; Kawahara H; Ozaki K; Fukura M; Yano H; Tsuchishima M; Tsutsumi M; Takase S
    Am J Gastroenterol; 2007 Sep; 102(9):1931-8. PubMed ID: 17511754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum cytokeratin-18 fragment level: a noninvasive biomarker for not only nonalcoholic steatohepatitis, but also alcoholic steatohepatitis.
    Li X; Zhang Y; Wu K; Fan D
    Hepatology; 2010 May; 51(5):1865-6. PubMed ID: 20041411
    [No Abstract]   [Full Text] [Related]  

  • 25. Significance and practicability of Normotest in diagnosis of chronic liver diseases.
    Henning H; Yano M
    Scand J Gastroenterol Suppl; 1973; 19():119-23. PubMed ID: 4515634
    [No Abstract]   [Full Text] [Related]  

  • 26. Pathology of nonalcoholic fatty liver disease.
    Yeh MM; Brunt EM
    Am J Clin Pathol; 2007 Nov; 128(5):837-47. PubMed ID: 17951208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non alcoholic steatohepatitis.
    Zantout H; Barada K
    J Med Liban; 2001; 49(2):90-3. PubMed ID: 11910973
    [No Abstract]   [Full Text] [Related]  

  • 28. Laparoscopic findings in patients with nonalcoholic steatohepatitis.
    Tanaka N; Ichijo T; Okiyama W; Mutou H; Misawa N; Matsumoto A; Yoshizawa K; Tanaka E; Kiyosawa K
    Liver Int; 2006 Feb; 26(1):32-8. PubMed ID: 16420508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Significance of lecithin-cholesterol acyltransferase analysis in clinical tests].
    Itakura H
    Nihon Rinsho; 1989 Dec; 48 Suppl():564-7. PubMed ID: 2621951
    [No Abstract]   [Full Text] [Related]  

  • 30. Metabolic aspects of hepatitis C viral infection: steatohepatitis resembling but distinct from NASH.
    Koike K; Moriya K
    J Gastroenterol; 2005 Apr; 40(4):329-36. PubMed ID: 15868369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypertension and fatty liver: guilty by association?
    Brookes MJ; Cooper BT
    J Hum Hypertens; 2007 Apr; 21(4):264-70. PubMed ID: 17273155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?
    Hui JM; Hodge A; Farrell GC; Kench JG; Kriketos A; George J
    Hepatology; 2004 Jul; 40(1):46-54. PubMed ID: 15239085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Definitive diagnosis and assessment of risk for nonalcoholic fatty liver disease in children and adolescents.
    Schwimmer JB
    Semin Liver Dis; 2007 Aug; 27(3):312-8. PubMed ID: 17682977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future.
    Wieckowska A; McCullough AJ; Feldstein AE
    Hepatology; 2007 Aug; 46(2):582-9. PubMed ID: 17661414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Relationship between morphological diagnosis of NASH (non-alcoholic steatohepatitis) and liver function tests in a group of patients with morbid obesity].
    Chavarría-Arciniega S; López-Alvarenga JC; Uribe-Uribe NO; Herrera-Hernández M; González-Barranco J
    Rev Invest Clin; 2005; 57(4):505-12. PubMed ID: 16315634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease.
    Miele L; Forgione A; La Torre G; Vero V; Cefalo C; Racco S; Vellone VG; Vecchio FM; Gasbarrini G; Rapaccini GL; Neuman MG; Grieco A
    Transl Res; 2009 Oct; 154(4):194-201. PubMed ID: 19766963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-alcoholic steatohepatitis in children.
    Roberts EA
    Clin Liver Dis; 2007 Feb; 11(1):155-72, x. PubMed ID: 17544977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease.
    Pagadala M; Zein CO; McCullough AJ
    Clin Liver Dis; 2009 Nov; 13(4):591-606. PubMed ID: 19818307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity.
    Tsochatzis E; Papatheodoridis GV; Hadziyannis E; Georgiou A; Kafiri G; Tiniakos DG; Manesis EK; Archimandritis AJ
    Scand J Gastroenterol; 2008; 43(9):1128-36. PubMed ID: 18609175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leptin a new biological marker for evaluating malnutrition in elderly patients.
    Bouillanne O; Golmard JL; Coussieu C; Noël M; Durand D; Piette F; Nivet-Antoine V
    Eur J Clin Nutr; 2007 May; 61(5):647-54. PubMed ID: 17151588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.